On 3 February 2015, the FDA granted accelerated approval of Palbociclib (in combination with letrozole) for postmenopausal women with advanced breast cancer, then in 2016 Palbociclib was approved for treatment of HR+/HER2− metastatic BC. The gene discussed is ERBB2; the disease is breast cancer.